Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru



ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Практическая пульмонология (ранее – "Атмосфера. Пульмонология и аллергология"): ISSN 2409-756X (Online), ISSN 2409-6636 (Print)
2018 / N 1

Безопасная отмена ингаляционной глюкокортикостероидной терапии у пациентов с хронической обструктивной болезнью легких
А.С. Белевский, З.Р. Айсанов

References
1. Aisanov ZR, Avdeev SN, Arkhipov VV, Belevskiy AS, Leshchenko IV, Ovcharenko SI, Shmelev EI, Chuchalin AG. National clinical guidelines on diagnosis and treatment of chronic obstructive pulmonary disease: a clinical decision-making algorithm. Russian Pulmonology 2017;27(1):13-20 (In Russian).
2. Aisanov Z, Avdeev S, Arkhipov V, Belevskiy A, Chuchalin A, Leshchenko I, Ovcharenko S, Shmelev E, Miravitlles M. Russian guidelines for the management of COPD: algorithm of pharmacologic treatment. International Journal of Chronic Obstructive Pulmonary Disease 2018;13:183-7.
3. Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, Frith P, Halpin DM, López Varela MV, Nishimura M, Roche N, Rodriguez-Roisin R, Sin DD, Singh D, Stockley R, Vestbo J, Wedzicha JA, Agusti A. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary. The European Respiratory Journal 2017 Mar;49(3). pii: 1700214. doi: 10.1183/13993003.00214-2017.
4. Vestbo J, Vogelmeier C, Small M, Higgins V. Understanding the GOLD 2011 strategy as applied to a real-world COPD population. Respiratory Medicine 2014 May;108(5):729-36.
5. Safka KA, Wald J, Wang H, McIvor L, McIvor A. GOLD stage and treatment in COPD: a 500 patient point prevalence study. Chronic Obstructive Pulmonary Diseases 2017;4(1):45-55.
6. Brusselle G, Price D, Gruffydd-Jones K, Miravitlles M, Keininger DL, Stewart R, Baldwin M, Jones RC. The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK. International Journal of Chronic Obstructive Pulmonary Disease 2015 Oct;10:2207-17.
7. Barnes PJ. Inhaled corticosteroids. Pharmaceuticals (Basel) 2010 Mar;3(3):514-40.
8. Barnes NC, Qiu YS, Pavord ID, Parker D, Davis PA, Zhu J, Johnson M, Thomson NC, Jeffery PK; SCO30005 Study Group. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. American Journal of Respiratory and Critical Care Medicine 2006 Apr;173(7):736-43.
9. Lapperre TS, Snoeck-Stroband JB, Gosman MM, Jansen DF, van Schadewijk A, Thiadens HA, Vonk JM, Boezen HM, Ten Hacken NH, Sont JK, Rabe KF, Kerstjens HA, Hiemstra PS, Timens W, Postma DS, Sterk PJ; Groningen Leiden Universities Corticosteroids in Obstructive Lung Disease Study Group. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine 2009 Oct;151(8):517-27.
10. Kunz LIZ, Ten Hacken NH, Lapperre TS, Timens W, Kerstjens HAM, van Schadewijk A, Vonk JM, Sont JK, Snoeck-Stroband JB, Postma DS, Sterk PJ, Hiemstra PS; GLUCOLD Study Group. Airway inflammation in COPD after long-term withdrawal of inhaled corticosteroids. The European Respiratory Journal 2017 Jun;49(6). pii: 1700848. doi: 10.1183/13993003.00848-2017.
11. Asai K, Kobayashi A, Makihara Y, Johnson M. Anti-inflammatory effects of salmeterol/fluticasone propionate 50/250 mcg combination therapy in Japanese patients with chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease 2015 Apr;10:803-11.
12. Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet 1998 Mar;351(9105):773-80.
13. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000 May;320(7245):1297-303.
14. Nannini LJ, Poole P, Milan SJ, Kesterton A. Combined corticosteroid and long-acting beta2-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease. The Cochrane Database of Systematic Reviews 2013 Aug;(8):CD006826.
15. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J; TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. The New England Journal of Medicine 2007 Feb;356(8):775-89.
16. Suissa S, Ernst P. Mega trials in COPD – clinical data analysis and design issues. Pneumonologia I Alergologia Polska 2011;79(3):227-31.
17. Vestbo J, Anderson JA, Brook RD, Calverley PM, Celli BR, Crim C, Martinez F, Yates J, Newby DE; SUMMIT Investigators. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet 2016 Apr;387(10030):1817-26.
18. Siva R, Green RH, Brightling CE, Shelley M, Hargadon B, McKenna S, Monteiro W, Berry M, Parker D, Wardlaw AJ, Pavord ID. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. The European Respiratory Journal 2007 May;29(5):906-13.
19. Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. The Lancet Respiratory Medicine 2015 Jun;3(6):435-42.
20. Siddiqui SH, Guasconi A, Vestbo J, Jones P, Agusti A, Paggiaro P, Wedzicha J, Singh D. Blood eosinophils: a biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 2015 Aug;192(4):523-5.
21. Hinds DR, DiSantostefano RL, Le HV, Pascoe S. Identification of responders to inhaled corticosteroids in a chronic obstructive pulmonary disease population using cluster analysis. BMJ Open 2016 Jun;6(6):e010099. doi: 10.1136/bmjopen-2015-010099.
22. Barnes NC, Sharma R, Lettis S, Calverley PM. Blood eosinophils as a marker of response to inhaled corticosteroids in COPD. The European Respiratory Journal 2016 May;47(5):1374-82.
23. Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley RA; INSPIRE Investigators. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. American Journal of Respiratory and Critical Care Medicine 2008 Jan;177(1):19-26. 24. Vogelmeier CF, Bateman ED, Pallante J, Alagappan VK, D’Andrea P, Chen H, Banerji D. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. The Lancet Respiratory Medicine 2013 Mar;1(1):51-60.
25. Singh D, Worsley S, Zhu CQ, Hardaker L, Church A. Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial. BMC Pulmonary Medicine 2015 Aug;15:91.
26. Beeh KM, Derom E, Echave-Sustaeta J, Grönke L, Hamilton A, Zhai D, Bjermer L. The lung function profile of once-daily tiotropium and olodaterol via Respimat® is superior to that of twice-daily salmeterol and fluticasone propionate via A Accuhaler® (ENERGITO® study). International Journal of Chronic Obstructive Pulmonary Disease 2016 Feb;11:193-205.
27. Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, Thach C, Fogel R, Patalano F, Vogelmeier CF; FLAME Investigators. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. The New England Journal of Medicine 2016 Jun;374(23):2222-34.
28. Vogelmeier CF, Chapman KR, Miravitlles M, Roche N, Vestbo J, Thach C, Banerji D, Fogel R, Patalano F, Olsson P, Kostikas K, Wedzicha JA. Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study. International Journal of Chronic Obstructive Pulmonary Disease 2018 Apr;13:1125-34.
29. Roche N, Chapman KR, Vogelmeier CF, Herth FJF, Thach C, Fogel R, Olsson P, Patalano F, Banerji D, Wedzicha JA. Blood eosinophils and response to maintenance chronic obstructive pulmonary disease treatment: data from the FLAME trial. American Journal of Respiratory and Critical Care Medicine 2017 May;195(9):1189-97.
30. Papi A, Kostikas K, Wedzicha JA, Vogelmeier CF, Roche N, Shen S, Banerji D, Fogel R, Patalano F, Chapman KR. Dual bronchodilation response by exacerbation history and eosinophilia in the FLAME study. American Journal of Respiratory and Critical Care Medicine 2018 May;197(9):1223-6.
31. Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Archives of Internal Medicine 2009 Feb;169(3):219-29.
32. Loke YK, Cavallazzi R, Singh S. Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies. Thorax 2011 Aug;66(8):699-708.
33. Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. The American Journal of Medicine 2010 Nov; 123(11):1001-6.
34. Gonzalez AV, Li G, Suissa S, Ernst P. Risk of glaucoma in elderly patients treated with inhaled corticosteroids for chronic airflow obstruction. Pulmonary Pharmacology and Therapeutics 2010 Apr;23(2):65-70.
35. Nath T, Roy SS, Kumar H, Agrawal R, Kumar S, Satsangi SK. Prevalence of steroid-induced cataract and glaucoma in chronic obstructive pulmonary disease patients attending a tertiary care center in India. Asia-Pacific Journal of Ophthalmology (Philadelphia, Pa.) 2017 Jan-Feb;6(1):28-32.
36. Roland NJ, Bhalla RK, Earis J. The local side effects of inhaled corticosteroids: current understanding and review of the literature. Chest 2004 Jul;126(1):213-9.
37. Kim JH, Park JS, Kim KH, Jeong HC, Kim EK, Lee JH. Inhaled corticosteroid is associated with an increased risk of TB in patients with COPD. Chest 2013 Apr;143(4):1018-24.
38. Crim C, Dransfield MT, Bourbeau J, Jones PW, Hanania NA, Mahler DA, Vestbo J, Wachtel A, Martinez FJ, Barnhart F, Lettis S, Calverley PM. Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. Annals of the American Thoracic Society 2015 Jan;12(1):27-34.
39. Singh S, Loke YK. Risk of pneumonia associated with long-term use of inhaled corticosteroids in chronic obstructive pulmonary disease: a critical review and update. Current Opinion in Pulmonary Medicine 2010 Mar;16(2):118-22.
40. Lehouck A, Boonen S, Decramer M, Janssens W. COPD, bone metabolism, and osteoporosis. Chest 2011 Mar;139(3):648-57.
41. Jarad NA, Wedzicha JA, Burge PS, Calverley PM. An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. ISOLDE Study Group. Respiratory Medicine 1999 Mar;93(3):161-6.
42. van der Valk P, Monninkhof E, van der Palen J, Zielhuis G, van Herwaarden C. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. American Journal of Respiratory and Critical Care Medicine 2002 Nov;166(10):1358-63.
43. Wouters EF, Postma DS, Fokkens B, Hop WC, Prins J, Kuipers AF, Pasma HR, Hensing CA, Creutzberg EC; COSMIC (COPD and Seretide: a Multi-Center Intervention and Characterization) Study Group. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. Thorax 2005 Jun;60(6):480-7.
44. Choudhury AB, Dawson CM, Kilvington HE, Eldridge S, James WY, Wedzicha JA, Feder GS, Griffiths CJ. Withdrawal of inhaled corticosteroids in people with COPD in primary care: a randomised controlled trial. Respiratory Research 2007 Dec;8:93.
45. Nadeem NJ, Taylor SJ, Eldridge SM. Withdrawal of inhaled corticosteroids in individuals with COPD – a systematic review and comment on trial methodology. Respiratory Research 2011 Aug;12:107.
46. Calzetta L, Matera MG, Braido F, Contoli M, Corsico A, Di Marco F, Santus P, Scichilone N, Cazzola M, Rogliani P. Withdrawal of inhaled corticosteroids in COPD: a meta-analysis. Pulmonary Pharmacology & Therapeutics 2017 Aug;45:148-58.
47. Rossi A, van der Molen T, del Olmo R, Papi A, Wehbe L, Quinn M, Lu C, Young D, Cameron R, Bucchioni E, Altman P. INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD. The European Respiratory Journal 2014 Dec;44(6):1548-56.
48. Frith P, Ashmawi S, Krishnamurthy S, Diaz D, Gurgun A, Hours-Zesiger P, Hristoskova S, Pilipovic V. Assessing direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in moderate to severe symptomatic COPD patients: the FLASH study. Respirology 2017 Nov;22(S3):AOL011
49. Rossi A, Guerriero M, Corrado A; OPTIMO/AIPO Study Group. Withdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO). Respiratory Research 2014 Jul;15:77.
50. Vogelmeier CF, Gaga M, Aalamian-Mattheis M, Greulich T, Marin JM, Castellani W, Ninane V, Lane S, Nunez X, Patalano F, Clemens A, Kostikas K; CRYSTAL study investigators. Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial. Respiratory Research 2017 Jul;18(1):140.
51. Greulich T, Kostikas K, Gaga M, Aalamian-Mattheis M, Lossi NS, Patalano F, Nunez X, Pagano VA, Fogel R, Vogelmeier CF, Clemens A. Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study. International Journal of Chronic Obstructive Pulmonary Disease 2018 Apr;13:1229-37.
52. Vogelmeier C, Worth H, Buhl R, Criée CP, Lossi NS, Mailänder C, Kardos P. "Real-life" inhaled corticosteroid withdrawal in COPD: a subgroup analysis of DACCORD. International Journal of Chronic Obstructive Pulmonary Disease 2017 Feb;12:487-94.
53. Magnussen H, Disse B, Rodriguez-Roisin R, Kirsten A, Watz H, Tetzlaff K, Towse L, Finnigan H, Dahl R, Decramer M, Chanez P, Wouters EF, Calverley PM; WISDOM Investigators.. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. The New England Journal of Medicine 2014 Oct;371(14):1285-94.
54. Jones PW, Beeh KM, Chapman KR, Decramer M, Mahler DA, Wedzicha JA. Minimal clinically important differences in pharmacological trials. American Journal of Respiratory and Critical Care Medicine 2014 Feb;189(3):250-5.
55. Magnussen H, Tetzlaff K, Bateman ED, Watz H, Kirsten AM, Wouters EF, Disse B, Finnigan H, Rodriguez-Roisin R, Calverley PM. Lung function changes over time following withdrawal of inhaled corticosteroids in patients with severe COPD. The European Respiratory Journal 2016 Feb;47(2):651-4.
56. Watz H, Tetzlaff K, Wouters EF, Kirsten A, Magnussen H, Rodriguez-Roisin R, Vogelmeier C, Fabbri LM, Chanez P, Dahl R, Disse B, Finnigan H, Calverley PM. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. The Lancet Respiratory Medicine 2016 May;4(5):390-8.
57. Suissa S, Coulombe J, Ernst P. Discontinuation of inhaled corticosteroids in COPD and the risk reduction of pneumonia. Chest 2015 Nov;148(5):1177-83.
58. Miravitlles M, Cosío BG, Arnedillo A, Calle M, Alcázar-Navarrete B, González C, Esteban C, Trigueros JA, Rodríguez González-Moro JM, Quintano Jiménez JA, Baloira A. A proposal for the withdrawal of inhaled corticosteroids in the clinical practice of chronic obstructive pulmonary disease. Respiratory Research 2017 Nov;18(1):198.
59. Kaplan AG Rodriguez MR, Tsiligianni I, Price D. Desktop helper: a guidance tool on appropriateness of inhaled corticosteroid (ICS) therapy and ICS withdrawal in patients with COPD, Asian Pacific Society of Respirology (APSR) 2017 Respirology 2017;22(S3):AP242.
  

[ Содержание выпуска N 1 | Выпуски журнала | Список журналов ]